Detalles de la búsqueda
1.
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
N Engl J Med
; 390(11): 994-1008, 2024 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38477987
2.
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.
Ann Hematol
; 102(2): 349-358, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36564535
3.
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
Ann Hematol
; 102(10): 2741-2752, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37592092
4.
Impact of single-room contact precautions on acquisition and transmission of vancomycin-resistant enterococci on haematological and oncological wards, multicentre cohort-study, Germany, January-December 2016.
Euro Surveill
; 27(2)2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35027104
5.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 22(4): 463-475, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33684370
6.
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q).
Ann Hematol
; 100(6): 1463-1471, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33903952
7.
Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
Future Oncol
; 16(36): 3035-3043, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32902312
8.
Controlling intestinal colonization of high-risk haematology patients with ESBL-producing Enterobacteriaceae: a randomized, placebo-controlled, multicentre, Phase II trial (CLEAR).
J Antimicrob Chemother
; 74(7): 2065-2074, 2019 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31220256
9.
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.
Haematologica
; 104(5): 955-962, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30514803
10.
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
Haematologica
; 103(8): 1298-1307, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29773593
11.
Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
Ann Hematol
; 96(6): 887-894, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28374162
12.
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Br J Haematol
; 172(1): 97-110, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26537529
13.
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
Haematologica
; 101(9): 1065-73, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27247324
14.
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
Am J Hematol
; 91(12): 1206-1214, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27531525
15.
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
Haematologica
; 100(7): 898-904, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25887498
16.
A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies.
J Antimicrob Chemother
; 69(12): 3387-92, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25103492
17.
Bosutinib: a novel second-generation tyrosine kinase inhibitor.
Recent Results Cancer Res
; 201: 81-97, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24756786
18.
Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial.
Front Oncol
; 14: 1283266, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38384801
19.
Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Ann Hematol
; 92(4): 487-96, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23250623
20.
Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma.
Front Oncol
; 13: 1107134, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37427101